NASDAQ:AERI - Aerie Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$70.45 +3.10 (+4.60 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$67.35
Today's Range$65.70 - $71.30
52-Week Range$47.05 - $71.30
Volume1.20 million shs
Average Volume366,438 shs
Market Capitalization$2.60 billion
P/E Ratio-20.91
Dividend YieldN/A
Beta0.94
Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300

Debt

Debt-to-Equity Ratio0.52
Current Ratio13.57
Quick Ratio13.53

Price-To-Earnings

Trailing P/E Ratio-20.91
Forward P/E Ratio-18.79
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.60 per share
Price / Book19.57

Profitability

EPS (Most Recent Fiscal Year)($3.37)
Net Income$-145,100,000.00
Net MarginsN/A
Return on Equity-84.90%
Return on Assets-46.26%

Miscellaneous

Employees160
Outstanding Shares39,500,000

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals Inc (NASDAQ:AERI) posted its earnings results on Tuesday, May, 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.04. View Aerie Pharmaceuticals' Earnings History.

What price target have analysts set for AERI?

10 brokers have issued 1 year price objectives for Aerie Pharmaceuticals' stock. Their predictions range from $68.00 to $86.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $77.6667 in the next twelve months. View Analyst Ratings for Aerie Pharmaceuticals.

What are Wall Street analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
  • 1. Mizuho analysts commented, "We had the opportunity to host lunch for Rubino yesterday. The company began to see strong uptake of Rhopressa following the product launch on and feedback from the salesforce has been very positive. We are confident in management’s ability to execute." (6/1/2018)
  • 2. Canaccord Genuity analysts commented, "We continue to view Aerie positively, with catalysts for Roclatan, OUS geographies and additional clinical progression as potential inflection points that build on what will likely be solid acceptance of Rhopressa. We maintain our BUY rating and DCF-driven $86 PT on AERI shares." (5/15/2018)
  • 3. According to Zacks Investment Research, "Aerie received a significant boost with the recent approval of lead drug Rhopressa. The approval came ahead of the PDUFA date. Meanwhile, Aerie is also evaluating Roclatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Aerie’s shares have outperformed the industry in the last  twelve months. However, Rhopressa faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Valeant Pharmaceutical’s Vyzulta is also approved for open-angle glaucoma or ocular hypertension. Rhopressa will face a tough time in gaining market share due to competition from these products. Any approval delays for Roclatan like Rhopressa will be detrimental to the company's growth prospects." (4/17/2018)

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:
  • Dr. Vincente J. Anido Jr., Ph.D., Chairman & CEO (Age 65)
  • Mr. Thomas A. Mitro, Pres & COO (Age 60)
  • Mr. Richard James Rubino CPA, CFO & Sec. (Age 60)
  • Dr. Casey C. Kopczynski Ph.D., Co-Founder & Chief Scientific Officer (Age 57)
  • Ms. Jessica Crespo CPA, Director of Accounting

Has Aerie Pharmaceuticals been receiving favorable news coverage?

Media coverage about AERI stock has been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a media sentiment score of 0.10 on Accern's scale. They also gave press coverage about the company an impact score of 45.93 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.95%), Columbus Circle Investors (1.60%), Summit Trail Advisors LLC (1.11%), Northern Trust Corp (1.10%), Millennium Management LLC (0.98%) and Neuberger Berman Group LLC (0.81%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Geoffrey M Duyk, Gerald D Cagle and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.

Which institutional investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Barclays PLC, Russell Investments Group Ltd., Citigroup Inc., Suffolk Capital Management LLC, BlackRock Inc., Millennium Management LLC and Eversept Partners LLC. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.

Which institutional investors are buying Aerie Pharmaceuticals stock?

AERI stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Highland Capital Management LP, Handelsbanken Fonder AB, Handelsbanken Fonder AB, OppenheimerFunds Inc., Neuberger Berman Group LLC, PointState Capital LP and Columbus Circle Investors. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP and Gerald D Cagle. View Insider Buying and Selling for Aerie Pharmaceuticals.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $70.45.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $2.60 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]


MarketBeat Community Rating for Aerie Pharmaceuticals (AERI)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  496 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  653
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.